Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study
Yael Kusne(University of Arizona), Mohamad Bassam Sonbol(Mayo Clinic), Shaylene McCue(WinnMed), Fang‐Shu Ou(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic in Arizona), Tanios Bekaii‐Saab(AstraZeneca (United Kingdom)), Zaid Elsabbagh(Apple (Israel)), Christy M. Finke(Mayo Clinic), Timothy J. Hobday(Mayo Clinic), Terra L. Lasho(Mayo Clinic), Þorvarður R. Hálfdánarson(Mayo Clinic), Jason S. Starr(Mayo Clinic in Florida)
Cited by 5
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396